ArticleJournal of immunology and clinical research2018
Assessment and Treatment Strategies for a Multiple Sclerosis Relapse.
Article in Journal of immunology and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Measuring treatment response to advance precision medicine for multiple sclerosis.Annals of clinical and translational neurology · 2021Trial
- Validation of rule-based detection methods for relapse in multiple sclerosis.BMC medical informatics and decision making · 2026Article
- Characteristics of Disease Relapses and Their Relationships with Weather Conditions in Patients with Multiple Sclerosis.Journal of clinical medicine · 2025Article
- Gait Analysis in Neurorehabilitation: From Research to Clinical Practice.Bioengineering (Basel, Switzerland) · 2023Review
- Methylprednisolone-Induced Symptomatic Sinus Bradycardia in a Multiple Sclerosis Patient: A Case Report.Cureus · 2022Article
- Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2021Article
- Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.Frontiers in neurology · 2017Review
- Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?Multiple sclerosis journal - experimental, translational and clinicalArticle
- Factors Involved in Relapse of Multiple Sclerosis.Journal of microscopy and ultrastructureReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Relapses are the hallmark features of relapsing-remitting multiple sclerosis (RRMS). True relapses may be challenging to accurately diagnose. A clinician must rely on a combination of history, exam findings, laboratory studies, and neuroimaging to decide whether or not to treat for a presumed relapse. Although many consider MRI as the gold standard diagnostic test, it may not be rapidly accessible and still could miss lesions. In light of this diagnostic complexity, future directions including development and validation of a scale to assess MS relapse probability and severity would be useful to multiple sclerosis specialists and practicing neurologists. Given the complex pathophysiology of MS, more research is needed to ascertain the validity of promising biomarkers for predicting relapse.
Identifiers
30417033PMC6223639W3018215664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.